LU91564I2 - Combinaison comprenant de l'aliskiren, comme base libre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT - Google Patents

Combinaison comprenant de l'aliskiren, comme base libre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT

Info

Publication number: LU91564I2
Authority: LU; Luxembourg
Prior art keywords: opt; substd; alkylene; cooh; mono
Prior art date: 1994-04-18

Application number

LU91564C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-18

Filing date

2009-05-06

Publication date

2009-07-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91564(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-06 Application filed by Novartis Ag filed Critical Novartis Ag

2009-07-06 Publication of LU91564I2 publication Critical patent/LU91564I2/fr

Links

150000003839 salts Chemical class 0.000 title abstract 3
UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title 1
229960004601 aliskiren Drugs 0.000 title 1
239000012458 free base Substances 0.000 title 1
229960002003 hydrochlorothiazide Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 14
125000002947 alkylene group Chemical group 0.000 abstract 12
125000003545 alkoxy group Chemical group 0.000 abstract 10
125000001589 carboacyl group Chemical group 0.000 abstract 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 8
125000000000 cycloalkoxy group Chemical group 0.000 abstract 8
125000001072 heteroaryl group Chemical group 0.000 abstract 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
125000000753 cycloalkyl group Chemical group 0.000 abstract 5
125000004414 alkyl thio group Chemical group 0.000 abstract 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
125000003302 alkenyloxy group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
125000005368 heteroarylthio group Chemical group 0.000 abstract 2
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
-1 thiocarbamoyl Chemical group 0.000 abstract 2
125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
239000007858 starting material Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
- C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Hydrogenated Pyridines (AREA)
Pyridine Compounds (AREA)
Pyrrole Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Peptides Or Proteins (AREA)

LU91564C 1994-04-18 2009-05-06 Combinaison comprenant de l'aliskiren, comme base libre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT LU91564I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH116994		1994-04-18

Publications (1)

Publication Number	Publication Date
LU91564I2 true LU91564I2 (fr)	2009-07-06

Family

ID=4204102

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU91373C LU91373I2 (fr)	1994-04-18	2007-10-31	Aliskiren ou ses sels pharmaceutiquement acceptables (rasilez)
LU91564C LU91564I2 (fr)	1994-04-18	2009-05-06	Combinaison comprenant de l'aliskiren, comme base libre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LU91373C LU91373I2 (fr)	1994-04-18	2007-10-31	Aliskiren ou ses sels pharmaceutiquement acceptables (rasilez)

Country Status (26)

Country	Link
US (5)	US5559111A (fr)
EP (1)	EP0678503B1 (fr)
JP (1)	JP3240322B2 (fr)
KR (1)	KR100353779B1 (fr)
CN (2)	CN1266118C (fr)
AT (1)	ATE183997T1 (fr)
AU (1)	AU699616B2 (fr)
BR (1)	BR1100656A (fr)
CA (1)	CA2147056C (fr)
CY (4)	CY2208B1 (fr)
CZ (1)	CZ287935B6 (fr)
DE (4)	DE122009000020I1 (fr)
DK (1)	DK0678503T3 (fr)
ES (1)	ES2137478T3 (fr)
FI (1)	FI118336B (fr)
GR (1)	GR3031997T3 (fr)
HU (2)	HU226860B1 (fr)
IL (1)	IL113403A (fr)
LU (2)	LU91373I2 (fr)
MY (1)	MY119161A (fr)
NL (2)	NL300296I2 (fr)
NO (4)	NO310410B1 (fr)
NZ (1)	NZ270936A (fr)
RU (1)	RU95105970A (fr)
TW (2)	TW366341B (fr)
ZA (3)	ZA953052B (fr)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4408534A1 (de) *	1994-03-14	1995-09-28	Hoechst Ag	Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) *	1994-04-18	2005-04-30	Novartis Ag	Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (fr) *	1994-12-08	1996-06-12	Ciba-Geigy Ag	Amides d'acides oméga-amino alcanoiques et diamides alcanoiques ayant un substituant aromatique et leur application en tant qu'inhibiteurs de leur rénine
US6465650B1 (en)	1995-03-13	2002-10-15	Aventis Pharma Deutschland Gmbh	Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
DK1045839T3 (da) *	1997-12-16	2004-07-05	Warner Lambert Co	Hidtil ukendte aminer som farmaceutiske midler
US7354894B2 (en) *	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en)	1998-08-18	2005-01-25	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US6833460B2 (en) *	1999-06-18	2004-12-21	E. I. Du Pont De Nemours And Company	Preparation and use of gamma-butyrolactones as cross-linking agents
US6423850B1 (en)	1999-06-18	2002-07-23	E.I. Du Pont De Nemours And Company	Preparation and use of gamma-butyrolactones as cross-linking agents
ATE406346T1 (de) *	1999-07-29	2008-09-15	Speedel Pharma Ag	Herstellung von n-substituierten 2,7-dialkyl-4- hydroxy-5-amino-8-aryl-octanoylamiden
EP1296912B1 (fr) *	2000-07-03	2006-01-25	Speedel Pharma AG	Procede de preparation de (r)-2-alkyle-3-phenyle-1-propanols
KR100690471B1 (ko)	2000-07-05	2007-03-09	스페델 파르마 아게	치환된 옥타노일 아미드의 제조방법
DE60103545T2 (de) *	2000-07-25	2005-08-25	Speedel Pharma Ag	Verfahren zur herstellung von substituierten octanoyl-amiden
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DK1215201T3 (da)	2000-12-14	2007-01-29	Speedel Pharma Ag	Fremgangsmåde til fremstilling af aryloctanylamider
JP3440082B2 (ja)	2001-02-19	2003-08-25	科学技術振興事業団	電気自動車用インホイールモーター
JP4252803B2 (ja)	2001-05-15	2009-04-08	シュペーデル・ファルマ・アーゲー	酵素加水分解による置換カルボン酸エステルの調製方法
JP2004535424A (ja) *	2001-06-11	2004-11-25	イーラン　ファーマスーティカルズ、インコーポレイテッド	アルツハイマー病の治療に有用な置換アミノアルコール
JP2005509631A (ja) *	2001-10-18	2005-04-14	ノバルティスアクチエンゲゼルシャフト	Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
US20050101638A1 (en) *	2002-11-08	2005-05-12	Webb Randy L.	Combination of organic compounds
BR0310084A (pt) *	2002-05-17	2005-02-15	Novartis Ag	Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
GB0212410D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Organic compounds
WO2003103652A1 (fr) *	2002-06-11	2003-12-18	Elan Pharmaceuticals, Inc.	Methodes de traitement de la maladie d'alzheimer au moyen d'amides d'acide o-amino-alcanoique a substitutions aromatiques et de diamides d'acide alcanoique
AU2003238007A1 (en) *	2002-06-11	2003-12-22	Elan Pharmaceuticals, Inc.	Methods of treating alzheimer's disease using aryl alkanoic acid amides
EP1539754A4 (fr) *	2002-08-23	2009-02-25	Novartis Vaccines & Diagnostic	Quinolinones de benzimidazole et leurs utilisations
US7049469B2 (en)	2002-10-24	2006-05-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Process for preparing (R)-salbutamol
CA2507484A1 (fr) *	2002-11-27	2004-06-17	Elan Pharmaceuticals, Inc.	Urees et carbamates substitues
WO2004100871A2 (fr) *	2003-05-09	2004-11-25	Pharmacia Corporation	Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
MXPA06002188A (es) *	2003-08-25	2006-04-27	Warner Lambert Co	Nuevos compuestos antimicrobianos de ariloxazolidinona.
JP4884230B2 (ja) *	2003-11-26	2012-02-29	ノバルティスアーゲー	有機化合物
GB0327839D0 (en) *	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
PE20050596A1 (es) *	2003-12-19	2005-10-18	Novartis Ag	Microemulsion que comprende un inhibidor renina
KR20060130619A (ko) *	2004-01-22	2006-12-19	노파르티스 아게	유기 화합물의 조합물
ATE472524T1 (de) *	2004-01-23	2010-07-15	Novartis Ag	Diaminoalkohole und deren verwendung als renininhibitoren
BRPI0506491A (pt) *	2004-01-23	2007-02-13	Speedel Experimenta Ag	compostos orgánicos
PE20142101A1 (es)	2004-03-17	2014-12-27	Novartis Ag	Composiciones farmaceuticas de aliskiren
US20070191487A1 (en) *	2004-03-17	2007-08-16	Rigassi-Dietrich Petra G	Galenic formulations of organic compounds
NZ549535A (en)	2004-03-17	2010-11-26	Novartis Ag	Use of aliskiren for treating renal and other disorders
TW200609215A (en) *	2004-03-19	2006-03-16	Speedel Experimenta Ag	Organic compounds
EP1724259A1 (fr) *	2004-03-19	2006-11-22	Speedel Experimenta AG	Dérivés 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide substitués 2,7 et composés similaires comme inhibiteurs du rénin pour le traitement de hypertension
WO2005095876A1 (fr)	2004-04-01	2005-10-13	Cucumber Limited	Livraison et stockage de marchandises
AR050043A1 (es) *	2004-08-03	2006-09-20	Novartis Ag	Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
GB0419361D0 (en) *	2004-08-31	2004-10-06	Novartis Ag	Organic compounds
ES2384637T3 (es)	2004-10-08	2012-07-10	Novartis Ag	Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
TW200631929A (en) *	2004-12-10	2006-09-16	Speedel Experimenta Ag	ω -phenyloctanamides
TW200633983A (en) *	2004-12-10	2006-10-01	Speedel Experimenta Ag	5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
EP1844002A1 (fr) *	2005-02-02	2007-10-17	Vitae Pharmaceuticals, Inc.	1-acylamino-2-hydroxy-3-amino-w-arylalkanes comme inhibiteurs de la reine
US20080176947A1 (en) *	2005-03-11	2008-07-24	Peter Herold	Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors
CN101171230A (zh) *	2005-03-11	2008-04-30	斯皮德尔实验股份公司	用作肾素抑制剂的杂环取代的链烷酰胺
EP1861352B1 (fr) *	2005-03-17	2009-12-09	Basf Se	Procede pour produire des derives d'acide propionique 3-phenyle optiquement actifs et produits reactionnels en decoulant
GB0511686D0 (en) *	2005-06-08	2005-07-13	Novartis Ag	Organic compounds
CN101218218B (zh) *	2005-07-11	2012-10-10	诺瓦提斯公司	新型焦儿茶酚衍生物
EP1745778A3 (fr)	2005-07-20	2007-03-07	Speedel Experimenta AG	Diamino alcools comme agents thérapeutiques
JP2009502751A (ja)	2005-07-22	2009-01-29	メルクフロストカナダリミテツド	レニン阻害薬
BRPI0617166A2 (pt)	2005-09-17	2011-07-12	Speedel Experimenta Ag	derivados de 5-amino-4-hidróxi-7-(imidazo[1,2-a]piridin-6-ilmetil)-8-me til-nonamidia e compostos relacionados como inibidores de renina para o tratamento de hipertensão
EP1764098A1 (fr) *	2005-09-17	2007-03-21	Speedel Experimenta AG	Dérivés de diaminoalcols et leur utilization pour le traitement de la malaria, de la maladie d'Alzheimer et du SIDA
CA2622375A1 (fr) *	2005-09-17	2007-03-22	Speedel Experimenta Ag	Amides d'acide alcanoique substitues par des o-heterocycles satures
GB0519764D0 (en) *	2005-09-28	2005-11-09	Novartis Ag	Organic compounds
GB0521083D0 (en) *	2005-10-17	2005-11-23	Novartis Ag	Organic compounds
WO2007045551A2 (fr) *	2005-10-18	2007-04-26	Nicox S.A.	Nitroderives d'inhibiteurs de la renine
JP2009512715A (ja)	2005-10-21	2009-03-26	ノバルティスアクチエンゲゼルシャフト	レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
GB2431645A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de)	2005-10-28	2007-05-03	Reuter Chemischer Apparatebau Kg	Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) *	2006-02-24	2008-01-16	Novartis Ag	New salt
GB0605688D0 (en)	2006-03-21	2006-05-03	Novartis Ag	Organic compounds
WO2007123718A1 (fr) *	2006-03-31	2007-11-01	Vitae Pharmaceuticals, Inc.	1-HÉTÉROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALCANES
US8084485B2 (en) *	2006-03-31	2011-12-27	Vitae Pharmaceuticals, Inc.	6-(aminoalkyl)indazoles
AU2007234917B2 (en) *	2006-04-03	2011-05-12	Novartis Ag	Renin inhibitors for the treatment of hypertension
WO2007148775A1 (fr) *	2006-06-23	2007-12-27	Daiichi Sankyo Company, Limited	Composé à chaîne aminée
US8158790B2 (en)	2006-06-23	2012-04-17	Daiichi Sankyo Company, Limited	Cyclic amine compound
GB0612540D0 (en)	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
EP2049517B1 (fr)	2006-07-20	2013-11-27	Novartis AG	Derives d'amino-piperidine comme inhibiteurs de cetp
EP1911762A1 (fr)	2006-10-04	2008-04-16	Speedel Experimenta AG	aminoalcools et leurs utilisation comme inhibiteurs de rénine
PE20081157A1 (es) *	2006-11-07	2008-09-26	Novartis Ag	Forma cristalina de hemifumarato de alisquireno
MX2009004628A (es) *	2006-11-09	2009-05-15	Novartis Ag	Sal de alisquireno con acido orotico.
EP1938812A1 (fr) *	2006-12-22	2008-07-02	Speedel Pharma AG	Composition pharmaceutique utilisant aliskiren et avosentan
EP1958666A1 (fr)	2007-02-13	2008-08-20	Speedel Experimenta AG	Alcanamides substitués hétérocycliques en tant que composants thérapeutiques
WO2008113835A1 (fr) *	2007-03-21	2008-09-25	Novartis Ag	Procédé de préparation de la (r ou s)-5-{1-azido-3-[6-méthoxy-5-(3-méthoxy-propoxy)-pyridin-3-ylméthyl]-4-méthyl-pentyl}-3-alkyl-dihydro-furan-2-one
EP1972335A1 (fr) *	2007-03-23	2008-09-24	Krka	Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables
US8338620B2 (en) *	2007-04-03	2012-12-25	Novartis Ag	Methods for the production of C-8 lactam lactone compounds
EP2173696A1 (fr)	2007-07-11	2010-04-14	DSM IP Assets B.V.	Préparation d'un aldéhyde saturé
US20090076062A1 (en) *	2007-09-13	2009-03-19	Juergen Klaus Maibaum	Organic Compounds
US20090082458A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched aliskiren
CN101808630A (zh)	2007-09-28	2010-08-18	诺瓦提斯公司	阿利吉仑的盖仑制剂
DE102007049039A1 (de)	2007-10-11	2009-04-16	Reuter Chemischer Apparatebau Kg	Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
CN101910150B (zh)	2007-11-05	2013-09-18	诺瓦提斯公司	作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物
EP2220031A1 (fr)	2007-11-13	2010-08-25	Teva Pharmaceutical Industries Ltd.	Formes polymorphes de l'hémifumarate d'aliskiren et procédé pour la préparation de celles-ci
EP2062874B1 (fr)	2007-11-20	2014-12-17	KRKA, tovarna zdravil, d.d., Novo mesto	Procédé et intermédiaires pour la préparation d'aliskiren
MX2010006063A (es)	2007-12-03	2010-07-01	Novartis Ag	Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
EP2075244A1 (fr)	2007-12-24	2009-07-01	DSMIP Assets B.V.	Nouvelle voie pour la construction de blocs pour la fabrication d'inhibiteurs de la rénine
WO2009104939A2 (fr)	2008-02-22	2009-08-27	한올제약주식회사	Préparation pharmaceutique
US20110111022A1 (en)	2008-04-10	2011-05-12	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation
KR20100135936A (ko) *	2008-05-23	2010-12-27	테바 파마슈티컬 인더스트리즈 리미티드	알리스키렌 모노푸마레이트 및 이의 제조 방법
JP2011522829A (ja) *	2008-06-06	2011-08-04	テバファーマシューティカルインダストリーズリミティド	固体状のアリスキレン遊離塩基
EP2143425A1 (fr)	2008-07-11	2010-01-13	Ratiopharm GmbH	Tablettes d'aliskiren comprimées directement
WO2010024772A1 (fr) *	2008-08-29	2010-03-04	Medivir Ab	Inhibiteurs d'aspartyl protéases
EP2163245A1 (fr)	2008-09-10	2010-03-17	Novartis Ag	Inhibiteurs de la rénine pour le traitement du psoriasis
EP2189442B1 (fr)	2008-11-20	2014-10-01	Krka Tovarna Zdravil, D.D., Novo Mesto	Procédé et intermédiaires pour la préparation d'aliskiren
US20110287100A1 (en)	2009-01-28	2011-11-24	Sabine Desset-Brethes	Galenic Formulations of Organic Compounds
WO2010089105A2 (fr)	2009-02-05	2010-08-12	Krka, Tovarna Zdravil, D.D., Novo Mesto	Procédé de granulation activé par l'humidité
US8148576B2 (en) *	2009-02-05	2012-04-03	Teva Pharmaceutical Industries Ltd.	Solid state forms of aliskiren compounds
CA2753221A1 (fr)	2009-03-20	2010-09-23	Novartis Ag	Composition pharmaceutique comprenant de l'aliskirene
EP2408427A1 (fr)	2009-03-20	2012-01-25	Novartis AG	Formulations galéniques d'une combinaison de dose fixe de valsartan et d'aliskiren
BRPI1006780A2 (pt)	2009-04-01	2019-03-26	Lek Pharmaceuticals D. D.	processo para preparar um composto, processo para a preparação de 3-amino-2, 2-dimetilpropanamida,processo para preparar um agente terapêutico, profilático ou de diagnóstico, processo para preparar alisquireno, processo para preparar um derivado de criptoficina,uso de um composto,uso de 3-amino-2,2-dimetilpropanamida e uso de agente terapêutico,profilático ou de diagnóstico.
AU2010282623B2 (en) *	2009-08-11	2013-12-12	Massachusetts Institute Of Technology	The ring opening of lactones and lactams
US20120220663A1 (en)	2009-09-03	2012-08-30	Teva Pharmaceuticals Usa, Inc.	Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk)	2009-09-23	2015-06-10		Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (fr) *	2009-10-21	2011-04-28	CarboDesign LLC	Procédé pour la fabrication d'acides aryloctanoïques énantiomériquement purs tels que l'aliskiren
US8203005B2 (en) *	2009-10-29	2012-06-19	Carbo Design Llc	Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
CA2777455A1 (fr) *	2009-11-09	2011-05-12	Novadex Pharmaceuticals Ab	Nouveaux composes de 1,3-oxazolidine et utilisation de ces derniers comme inhibiteurs de la renine
US20110113995A1 (en) *	2009-11-13	2011-05-19	Lindsay Corporation	Method and apparatus for planting and irrigation
US20110137047A1 (en) *	2009-12-07	2011-06-09	CarboDesign LLC	Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
ES2758554T3 (es)	2009-12-08	2020-05-05	Univ Case Western Reserve	Aminoácidos gama para tratamiento de trastornos oculares
CN101774986B (zh)	2010-01-06	2012-03-28	浙江天宇药业股份有限公司	一种制备阿利克伦及其中间体的方法
CN102140068B (zh) *	2010-01-30	2015-03-11	浙江华海药业股份有限公司	阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
WO2011098258A1 (fr) *	2010-02-10	2011-08-18	Ratiopharm Gmbh	Sels d'aliskirène
AR080683A1 (es)	2010-03-16	2012-05-02	Novartis Ag	Composiciones farmaceuticas de aliskiren y metodos de administracion
TR201002256A1 (tr)	2010-03-24	2011-10-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Stabil aliskiren formülasyonları
EP2382967A1 (fr)	2010-04-21	2011-11-02	ratiopharm GmbH	Aliskiren sous forme d'une dispersion solide
EP2382969A1 (fr)	2010-04-30	2011-11-02	Sanovel Ilac Sanayi ve Ticaret A.S.	Formulations d'Aliskiren multi-couches
CN102241650B (zh) *	2010-05-14	2014-05-07	浙江九洲药业股份有限公司	用于制备阿立克仑的中间体化合物及相关制备方法
TW201202178A (en)	2010-06-04	2012-01-16	Chemo Iberica Sa	Process for producing Aliskiren
IT1402925B1 (it) *	2010-12-10	2013-09-27	Chemo Iberica Sa	Processo per la produzione di aliskiren
IT1400961B1 (it) *	2010-06-04	2013-07-05	Chemo Iberica Sa	Processo per la produzione di aliskiren
CN101913998A (zh) *	2010-07-06	2010-12-15	上海朴颐化学科技有限公司	4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (fr)	2010-09-09	2012-03-15	Teva Pharmaceutical Industries Ltd.	Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène
PT2630118E (pt)	2010-10-19	2015-02-10	Mylan Lab Ltd	Síntese do aliskiren
CN102001920B (zh)	2010-11-09	2013-05-15	常州制药厂有限公司	一种药物中间体的制备方法
CN102161627A (zh) *	2011-02-24	2011-08-24	中国药科大学	ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (fr)	2011-07-28	2013-01-30	Chemo Ibérica, S.A.	Procédé chimique pour l'ouverture de composés cycliques
CN102942477B (zh) *	2011-08-14	2015-12-02	浙江华海药业股份有限公司	辛烯酸衍生物及其制备方法
CN102351734B (zh) *	2011-09-05	2014-02-26	浙江普洛医药科技有限公司	一种阿利克仑的制备方法
WO2013045505A1 (fr)	2011-09-28	2013-04-04	Novartis Ag	Biomarqueurs pour traitement combiné par des agents sraa
US8703976B2 (en) *	2011-10-02	2014-04-22	Milan Soukup	Manufacturing process for 8-aryloctanoic acids such as Aliskiren
WO2013061224A1 (fr)	2011-10-25	2013-05-02	Jubilant Life Sciences Limited	Procédé de préparation d'aliskiren
WO2013118138A1 (fr)	2011-12-13	2013-08-15	Laboratories Ltd Mylan	Nouveau procédé de préparation d'inhibiteurs de rénine
CN103172533B (zh) *	2011-12-20	2016-05-04	博瑞生物医药（苏州）股份有限公司	一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) *	2012-01-11	2013-07-17	南京欧信医药技术有限公司	阿利克伦中间体及其制备方法和应用
US9090537B2 (en)	2012-02-17	2015-07-28	Mylan Laboratories Limited	Process for the preparation of aliskiren
WO2013124868A2 (fr)	2012-02-21	2013-08-29	Mylan Laboratories Limited	Forme solide d'un produit intermédiaire d'aliskirène
ITMI20120354A1 (it) *	2012-03-07	2013-09-08	Friulchem Spa	Processo per la produzione di aliskirene
WO2013144979A1 (fr)	2012-03-28	2013-10-03	Maylan Laboratories Ltd	Procédé pour la préparation d'aliskirène
EP2847096B1 (fr)	2012-05-11	2016-03-16	Novartis AG	Dispositif distributeur
WO2013171767A1 (fr)	2012-05-18	2013-11-21	Mylan Laboratories Limited	Procédé amélioré de préparation d'aliskiren
EP2810644A1 (fr)	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Formulation orale pour le traitement de maladies cardiovasculaires
ES2683245T3 (es) *	2013-06-27	2018-09-25	Patheon Austria Gmbh & Co Kg	Preparación de reactivos de Grignard usando un lecho fluidizado
WO2019241590A1 (fr)	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Procédés de traitement de l'hypertension au moyen d'une composition pharmaceutique de blocage du récepteur de l'angiotensine ii
CN112679448B (zh) *	2020-12-31	2022-08-19	苏州昊帆生物股份有限公司	N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) *	2022-09-19	2024-05-07	合肥工业大学	一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4337207A (en) *	1980-09-04	1982-06-29	Regents Of The University Of California	Biologically active catecholamine derivatives
US4729985A (en) *	1985-08-09	1988-03-08	Pfizer Inc.	Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) *	1988-07-08	1990-05-14	Zhongguo Yixuekexueyuan Yaowo Yanjiusuo	Ｎ―置換アミド誘導体
MY119161A (en) *	1994-04-18	2005-04-30	Novartis Ag	Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

1995
- 1995-03-30 MY MYPI95000816A patent/MY119161A/en unknown
- 1995-04-04 US US08/416,242 patent/US5559111A/en not_active Expired - Lifetime
- 1995-04-07 DE DE122009000020C patent/DE122009000020I1/de active Pending
- 1995-04-07 DE DE59506707T patent/DE59506707D1/de not_active Expired - Lifetime
- 1995-04-07 ES ES95810236T patent/ES2137478T3/es not_active Expired - Lifetime
- 1995-04-07 EP EP95810236A patent/EP0678503B1/fr not_active Expired - Lifetime
- 1995-04-07 AT AT95810236T patent/ATE183997T1/de active
- 1995-04-07 DE DE122007000071C patent/DE122007000071I2/de active Active
- 1995-04-07 DK DK95810236T patent/DK0678503T3/da not_active Application Discontinuation
- 1995-04-10 TW TW084103730A patent/TW366341B/zh active
- 1995-04-12 FI FI951771A patent/FI118336B/fi not_active IP Right Cessation
- 1995-04-12 NO NO19951441A patent/NO310410B1/no not_active IP Right Cessation
- 1995-04-12 AU AU16421/95A patent/AU699616B2/en not_active Ceased
- 1995-04-13 ZA ZA953052A patent/ZA953052B/xx unknown
- 1995-04-13 RU RU95105970/04A patent/RU95105970A/ru unknown
- 1995-04-13 ZA ZA953051A patent/ZA953051B/xx unknown
- 1995-04-13 CA CA002147056A patent/CA2147056C/fr not_active Expired - Lifetime
- 1995-04-13 NZ NZ270936A patent/NZ270936A/en not_active IP Right Cessation
- 1995-04-13 ZA ZA953050A patent/ZA953050B/xx unknown
- 1995-04-14 CZ CZ1995976A patent/CZ287935B6/cs not_active IP Right Cessation
- 1995-04-14 HU HU9501076A patent/HU226860B1/hu active Protection Beyond IP Right Term
- 1995-04-14 HU HU9501078A patent/HUT71701A/hu unknown
- 1995-04-15 TW TW084103732A patent/TW402582B/zh not_active IP Right Cessation
- 1995-04-17 CN CNB2004100346824A patent/CN1266118C/zh not_active Expired - Lifetime
- 1995-04-17 KR KR1019950008959A patent/KR100353779B1/ko not_active Expired - Lifetime
- 1995-04-17 CN CNB951050370A patent/CN1153759C/zh not_active Expired - Lifetime
- 1995-04-17 IL IL11340395A patent/IL113403A/en active Protection Beyond IP Right Term
- 1995-04-18 JP JP09253295A patent/JP3240322B2/ja not_active Expired - Lifetime
1996
- 1996-07-02 US US08/674,555 patent/US5654445A/en not_active Expired - Lifetime
- 1996-07-25 US US08/687,878 patent/US5627182A/en not_active Expired - Lifetime
- 1996-07-25 US US08/687,277 patent/US5646143A/en not_active Expired - Lifetime
1997
- 1997-02-14 US US08/800,671 patent/US5705658A/en not_active Expired - Lifetime
- 1997-05-07 BR BR1100656-0A patent/BR1100656A/pt active IP Right Grant
1999
- 1999-11-30 GR GR990403090T patent/GR3031997T3/el unknown
2000
- 2000-12-01 CY CY0000064A patent/CY2208B1/xx unknown
2007
- 2007-09-26 NL NL300296C patent/NL300296I2/nl unknown
- 2007-10-31 LU LU91373C patent/LU91373I2/fr unknown
- 2007-10-31 NO NO2007011C patent/NO2007011I1/no unknown
- 2007-10-31 CY CY200700027C patent/CY2007027I2/el unknown
2009
- 2009-04-24 NL NL300386C patent/NL300386I1/nl unknown
- 2009-05-06 LU LU91564C patent/LU91564I2/fr unknown
- 2009-05-11 CY CY2009006C patent/CY2009006I1/el unknown
- 2009-05-18 NO NO2009011C patent/NO2009011I2/no unknown
2011
- 2011-09-20 NO NO2011020C patent/NO2011020I1/no unknown
- 2011-09-27 CY CY2011015C patent/CY2011015I1/el unknown
- 2011-09-28 DE DE201112100052 patent/DE122011100052I1/de active Pending

Also Published As

Publication number	Publication date
KR950032037A (ko)	1995-12-20
US5559111A (en)	1996-09-24
DE122011100052I1 (de)	2012-01-19
JP3240322B2 (ja)	2001-12-17
FI951771A0 (fi)	1995-04-12
DK0678503T3 (da)	2000-03-20
NL300296I2 (nl)	2008-02-01
NO2007011I1 (no)	2007-12-11
EP0678503A1 (fr)	1995-10-25
AU699616B2 (en)	1998-12-10
NZ270936A (en)	1997-06-24
CZ287935B6 (cs)	2001-03-14
CN1117960A (zh)	1996-03-06
US5646143A (en)	1997-07-08
ZA953051B (en)	1995-10-18
CY2009006I2 (el)	2010-07-28
CN1153759C (zh)	2004-06-16
FI951771A7 (fi)	1995-10-19
CY2007027I1 (el)	2009-11-04
DE59506707D1 (de)	1999-10-07
CY2011015I2 (el)	2014-04-09
DE122007000071I2 (de)	2009-01-02
HK1070881A1 (en)	2005-06-30
ES2137478T3 (es)	1999-12-16
CY2009006I1 (el)	2010-07-28
CA2147056C (fr)	2005-10-25
NO951441D0 (no)	1995-04-12
CY2208B1 (en)	2002-11-08
IL113403A (en)	2001-07-24
GR3031997T3 (en)	2000-03-31
CY2007027I2 (el)	2009-11-04
CN1550491A (zh)	2004-12-01
NO310410B1 (no)	2001-07-02
ATE183997T1 (de)	1999-09-15
AU1642195A (en)	1995-10-26
HUT71701A (en)	1996-01-29
NO2011020I1 (no)	2011-09-26
NO951441L (no)	1995-10-19
IL113403A0 (en)	1995-07-31
CY2011015I1 (el)	2014-04-09
KR100353779B1 (ko)	2003-01-08
HUT74074A (en)	1996-10-28
ZA953050B (en)	1995-11-08
HU226860B1 (en)	2009-12-28
US5705658A (en)	1998-01-06
ZA953052B (en)	1995-10-18
DE122009000020I1 (de)	2009-08-06
NO2009011I2 (no)	2010-11-22
RU95105970A (ru)	1997-01-10
CZ97695A3 (en)	1995-11-15
US5627182A (en)	1997-05-06
DE122007000071I1 (de)	2008-01-31
TW366341B (en)	1999-08-11
NO2007011I2 (fr)	2011-07-25
BR1100656A (pt)	2000-06-06
TW402582B (en)	2000-08-21
EP0678503B1 (fr)	1999-09-01
NL300386I1 (nl)	2009-07-01
NL300296I1 (nl)	2007-12-03
MY119161A (en)	2005-04-30
FI118336B (fi)	2007-10-15
HU9501078D0 (en)	1995-06-28
HU9501076D0 (en)	1995-06-28
NO2009011I1 (no)	2009-06-02
LU91373I2 (fr)	2007-12-31
US5654445A (en)	1997-08-05
JPH0881430A (ja)	1996-03-26
CN1266118C (zh)	2006-07-26
CA2147056A1 (fr)	1995-10-19

Publication	Publication Date	Title
LU91564I2 (fr)	2009-07-06	Combinaison comprenant de l'aliskiren, comme base libre ou comme un de ses sels pharmaceutiquement acceptables, et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables-Rasilez HCT
CY1105466T1 (el)	2010-04-28	Ουδετepο λιποπολυμepες και λιποσωματικες συνθεσεις που το πepιεχουν
AR017111A1 (es)	2001-08-22	Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas
DK0434960T3 (da)	1996-10-14	Chirale 1,5-diiod-2-methoxy- eller benzyloxymellemprodukter
DE69016104D1 (de)	1995-03-02	Verdickte saure Flüssigzusammensetzung mit einem aminhaltigen fluoreszierenden Weissmacher-Agens (FWA), verwendbar als Bleichhilfsmittel.
BR8904383A (pt)	1990-04-17	Composto polimerico,composicao sensivel a radiacao e processo para a producao de um composto polimerico
FI973894A0 (fi)	1997-10-06	9-substituoidut porfyseenit
AUPP109097A0 (en)	1998-01-22	Napthalene derivatives
DK0953563T3 (da)	2003-07-28	Fremgangsmåde til fremstilling af depsipeptidderivater samt hidtil ukendte intermediater derfor
FI910689A0 (fi)	1991-02-13	Polymerfoereningar.
ATE92479T1 (de)	1993-08-15	Neue 1,3-oxazine.
PT90831A (pt)	1989-12-29	Processo para a preparacao de eteres da 2-amino-7-hidroxitetralina
PE10799A1 (es)	1999-02-10	Derivados de vinilpirrolidinon-cefalosporina